BridgeBio to Present Acoramidis Data at AHA Scientific Sessions
BridgeBio says it will present new acoramidis data on heart failure events in ATTR-CM at the American Heart Association Scientific Sessions 2026.
Related stories
Canada’s TSX Opens 0.79% Lower at 35,518.78
The S&P/TSX Composite Index was down 0.79% at 35,518.78 points at 9:30 a.m. ET on Tuesday. Shopify results weighed on the index, while investors watched the US midterm elections.
M impact | EQUITY | Nov 03, 2026, 02:32 PM UTC
Lindblad Expeditions Reports Quarterly Results for Period Ended September 30
M impact | EQUITY | Nov 03, 2026, 02:32 PM UTC
Madrigal Pharmaceuticals Reports Quarterly Results
Madrigal Pharmaceuticals reported results for the quarter ended September 30.
M impact | EQUITY | Nov 03, 2026, 02:32 PM UTC
Ball Reports Quarterly Results for Period Ended September 30
M impact | EQUITY | Nov 03, 2026, 02:32 PM UTC
Nordecon Signs €2.8 Million Construction Contract
Nordecon signed a building construction contract valued at €2.8 million plus VAT, with work expected to be completed in early 2028.
M impact | EQUITY | Nov 03, 2026, 02:32 PM UTC
Sotera Health Reports Quarterly Results for Period Ended September 30
Sotera Health Company reported results for the quarter ended September 30; no figures were provided.
M impact | EQUITY | Nov 03, 2026, 02:32 PM UTC